1-14 of 14
Markus Munder, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Arginine Depletion in Combination with Canavanine Supplementation Induces Massive Cell Death in Myeloma Cells By Interfering with Their Protein Metabolism and Bypassing Potential Rescue Mechanisms

Johannes Windschmitt, Björn Jacobi, MD, Yagmur Bülbül, Lilli Sester, Janine Tappe, Christof Hiebel, PhD, Christian Behl, PhD, Matthias Theobald, Markus Munder, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3205.
https://doi.org/10.1182/blood-2018-99-113396
Published: 2018
Journal Articles

A Predictive Score for Early Mortality during Induction Therapy in Newly Diagnosed Transplant-Eligible Multiple Myeloma - an Analysis from Five GMMG and HOVON Multicenter Phase III Trials

Elias K Mai, MD, Thomas Hielscher, PhD, Uta Bertsch, MD, Jana Schlenzka, MD, Hans Jürgen Salwender, Henk M Lokhorst, Markus Munder, MD, Bronno van der Holt, Christian Gerecke, MD, Michael Pfreundschuh, MD, Ulrich Duhrsen, Peter Brossart, MD, Sonja Zweegman, MD PhD, Kai Neben, Jens Hillengass, MD, Marc-Steffen S Raab, Dirk Hose, MD, Edo Vellenga, MD, Maximilian Merz, MD, Iris Breitkreutz, MD, Anna Jauch, Marie José Kersten, MD, Hans Martin, Hans-Walter Lindemann, Norma Peter, MD, Sandra Croockewit, MD, Igor Wolfgang Blau, MD, Christof Scheid, MD, Katja C. Weisel, Pieter Sonneveld, MDPhD, Hartmut Goldschmidt, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2016.
https://doi.org/10.1182/blood.V130.Suppl_1.2016.2016
Published: 2017
Journal Articles

Response-Adapted Lenalidomide Maintenance in Newly Diagnosed, Transplant-Eligible Multiple Myeloma: Results from the Multicenter Phase III GMMG-MM5 Trial

Hartmut Goldschmidt, MD, Elias K Mai, MD, Jan Dürig, MD, Christof Scheid, MD, Katja C. Weisel, Christina Kunz, Uta Bertsch, MD, Thomas Hielscher, PhD, Markus Munder, MD, Hans-Walter Lindemann, Barbara Huegle-Doerr, Dirk Hose, MD, Anja Seckinger, Stefanie Huhn, PhD, Anna Jauch, Bernhard Rabold, Ahmet Elmaagacli, MD, Christian Gerecke, MD, Peter Brossart, MD, Martin Goerner, MD, Helga Bernhard, MD, Martin Hoffmann, MD, Jens Hillengass, MD, Marc-Steffen S Raab, Igor Wolfgang Blau, MD, Mathias Hänel, MD, Hans Jürgen Salwender
Journal: Blood
Blood (2017) 130 (Supplement 1): 400.
https://doi.org/10.1182/blood.V130.Suppl_1.400.400
Published: 2017
Journal Articles

Direct Assessment of IgA and IgG Paraprotein By Hevylite Assay and Correlation to IMWG Response and Progression-Free Survival in Newly Diagnosed, Transplant-Eligible Multiple Myeloma Patients in the Prospective Phase III GMMG-MM5 Trial

Christof Scheid, MD, Anja Seckinger, Jan Dürig, MD, Katja C. Weisel, Christina Kunz, Uta Bertsch, MD, Thomas Hielscher, PhD, Markus Munder, MD, Hans-Walter Lindemann, Barbara Huegle-Doerr, Stefanie Huhn, PhD, Elias K Mai, MD, Anna Jauch, Bernhard Rabold, Christian Gerecke, MD, Peter Brossart, MD, Martin Goerner, MD, Helga Bernhard, MD, Martin Hoffmann, MD, Jens Hillengass, MD, Marc-Steffen S Raab, Igor Wolfgang Blau, MD, Mathias Haenel, Dirk Hose, MD, Hartmut Goldschmidt, MD, Hans Jürgen Salwender
Journal: Blood
Blood (2017) 130 (Supplement 1): 1784.
https://doi.org/10.1182/blood.V130.Suppl_1.1784.1784
Published: 2017
Journal Articles

The Prognostic and Predictive Value of IKZF1 and IKZF3 Expression in T-Cells in Patients with Multiple Myeloma

Mohamed H.S. Awwad, Katharina Kriegsmann, MD MBA, Julian Plaumann, Michael Benn, Jens Hillengass, MD, Marc-Steffen S Raab, Uta Bertsch, MD, Markus Munder, MD, Katja C. Weisel, Hans Jürgen Salwender, Mathias Hänel, MD, Roland Fenk, MD, Jan Dürig, MD, Carsten Müller-Tidow, Hartmut Goldschmidt, MD, Michael Hundemer
Journal: Blood
Blood (2017) 130 (Supplement 1): 1846.
https://doi.org/10.1182/blood.V130.Suppl_1.1846.1846
Published: 2017
Journal Articles

Addition of Cyclophosphamide to Pomalidomide and Dexamethasone in Case of Suboptimal Response to Pomalidomide and Dexamethasone Alone in Relapsed and/or Refractory Multiple Myeloma: Results of the GMMG-Perspective Trial

Katja C. Weisel, Hans Jürgen Salwender, Christof Scheid, MD, Manola Zago, Britta Besemer, Mathias Hänel, MD, Jan Dürig, MD, Markus Munder, MD, Hans-Walter Lindemann, Anja Seckinger, Christina Kunz, Axel Benner, Dirk Hose, MD, Anna Jauch, Lothar Kanz, Hartmut Goldschmidt, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1849.
https://doi.org/10.1182/blood.V130.Suppl_1.1849.1849
Published: 2017
Journal Articles

Improved Safety with the Use of Subcutaneous Bortezomib in Combination with Panobinostat and Dexamethasone: Preliminary Data from a Panobinostat Global Expanded Treatment Protocol

Andreas Guenther, MD, Lars-Olof Mügge, Mathias Haenel, MD, Fredrik H. Schjesvold, MD, Daniel Lechner, Sameer Yaser, Holger Hebart, MD, Heinz Gisslinger, Richard Greil, MD, Eberhard Gunsilius, MD, Martin Goerner, MD, Katja Weisel, Jan Dürig, MD, Mohamed Elemary, MD MSc,PhD, Denise Wolleschak, Stefan A. Klein, MD, Markus Munder, MD, Alexander Kiani, Hareth Nahi, Christian Junghanss, MD, Valerie Campello-Iddison, MD, Ythier Deniau, Xiaoshu Feng, Hermann Einsele, MD
Journal: Blood
Blood (2016) 128 (22): 5692.
https://doi.org/10.1182/blood.V128.22.5692.5692
Published: 2016
Journal Articles

Evaluation of Stem Cell Mobilization in Patients with Multiple Myeloma after Lenalidomide-Based Induction Chemotherapy within the GMMG-HD6 Trial

Patrick Wuchter, MD, Uta Bertsch, MD, Hans-Juergen Salwender, MD, Markus Munder, MD, Mathias Haenel, MD, Axel Benner, Natalia Becker, PhD, Roland Fenk, MD, Jan Duerig, MD, Igor Wolfgang Blau, MD, Katharina Lisenko, MD, Jens Hillengass, MD, Marc S. Raab, MD, Marc Andrea Baertsch, MD, Andrea Seidel-Glaetzer, Anthony D Ho, MD, Ullrich Graeven, MD, Christof Scheid, MD, Katja Weisel, MD, Hartmut Goldschmidt, MD
Journal: Blood
Blood (2016) 128 (22): 3373.
https://doi.org/10.1182/blood.V128.22.3373.3373
Published: 2016
Journal Articles

Interfering with Arginine Metabolism As a New Treatment Strategy for Multiple Myeloma

Bjoern Jacobi, MD, Lea Stroeher, MS, Nadine Leuchtner, Hakim Echchannaoui, PhD, Alexander Desuki, MD, Lara Kuerzer, Alice Habermeier, Edite Antunes, Eva Amann, John Bomalaski, MD, Closs Ellen, PhD Prof., Matthias Theobald, MD PhD, Markus Munder, MD
Journal: Blood
Blood (2015) 126 (23): 3005.
https://doi.org/10.1182/blood.V126.23.3005.3005
Published: 2015
Journal Articles

Clinical Risk Factors for Peripheral Neuropathy in Patients Treated with Subcutaneous or Intravenous Bortezomib for Newly Diagnosed Multiple Myeloma

Maximilian Merz, MD, Hans-Juergen Salwender, MD, Mathias Haenel, MD, Uta Bertsch, MD, Christina Kunz, Thomas Hielscher, Igor W. Blau, MD, Christof Scheid, MDPhD, Elias Karl Mai, MD, Dirk Hose, MD, Bärbel Schurich, Markus Munder, MD, Peter Brossart, MD, Christian Gerecke, MD, Hans Walter Lindemann, MD, Matthias Zeis, MD, Katja C. Weisel, Jan Duerig, MD, Hartmut Goldschmidt, MD
Journal: Blood
Blood (2015) 126 (23): 4233.
https://doi.org/10.1182/blood.V126.23.4233.4233
Published: 2015
Journal Articles

Influence of Renal Impairment and Genetic Risk Factors on Response to Induction Therapy in the HD4 and MM5 Trials of the GMMG

Christof Scheid, MDPhD, Thomas Hielscher, Uta Bertsch, MD, Christina Kunz, PhD, Hans Salwender, MD, Mathias Haenel, Maximilian Merz, Elias Karl Mai, MD, Dirk Hose, MD PhD, Baerbel Schurich, PhD, Markus Munder, MD, Ingo Schmidt-Wolf, MD, Christian Gerecke, MD, Walter Lindemann, MD, Matthias Zeis, MD, Katja Weisel, MD, Jan Duerig, MD, Anna Jauch, PhD, Hartmut Goldschmidt, MD
Journal: Blood
Blood (2014) 124 (21): 4777.
https://doi.org/10.1182/blood.V124.21.4777.4777
Published: 2014
Journal Articles

Subcutaneous Versus Intravenous Bortezomib in Two Different Induction Therapies for Newly Diagnosed Multiple Myeloma – Subgroup Analysis from the GMMG-MM5 Trial

Maximilian Merz, MD, Hans Salwender, MD, Mathias Hänel, MD, Uta Bertsch, MD, Christina Kunz, PhD, Thomas Hielscher, Igor W. Blau, MD, Christof Scheid, MDPhD, Elias Karl Mai, MD, Dirk Hose, MD, Baerbel Schurich, PhD, Markus Munder, MD, Ingo GH Schmidt-Wolf, MD, Christian Gerecke, MD, Hans Walter Lindemann, MD, Matthias Zeis, MD, Katja Weisel, MD, Jan Duerig, MD, Hartmut Goldschmidt, MD
Journal: Blood
Blood (2014) 124 (21): 3475.
https://doi.org/10.1182/blood.V124.21.3475.3475
Published: 2014
Journal Articles

Prognostic Value Of sFLC Ratio At Baseline On Response After Induction Therapy In Patients With Multiple Myeloma In The GMMG MM5 Trial

Mabast Moohialdin, Hans Salwender, MD, Uta Bertsch, MD, Jan Duerig, MD, Christina Kunz, PhD, Thomas Hielscher, Markus Zorn, Mathias Haenel, MD, Igor Wolfgang Blau, MD, PhD, Dirk Hose, Dr. med. dipl.-phys, Baerbel Schurich, PhD, Kai Neben, MD, Anja Seckinger, MD, Markus Munder, MD, Walter Lindemann, MD, Matthias Zeis, MD, Christian Gerecke, MD, Ingo GH Schmidt-Wolf, MD, Katja Weisel, MD, Christof Scheid, MD, Hartmut Goldschmidt, MD
Journal: Blood
Blood (2013) 122 (21): 1897.
https://doi.org/10.1182/blood.V122.21.1897.1897
Published: 2013
Journal Articles

GMMG MM5 Trial In Newly Diagnosed Multiple Myeloma To Evaluate PAd Vs VCD Induction Prior To High Dose Treatment Followed By Lenalidomide Consolidation and Maintenance – Final Analysis On Induction Therapy

Hartmut Goldschmidt, MD, Jan Duerig, MD, Uta Bertsch, MD, Christina Kunz, PhD, Thomas Hielscher, Mathias Haenel, MD, Igor Wolfgang Blau, MD, PhD, Dirk Hose, Dr. med. dipl.-phys, Anna Jauch, PhD, Baerbel Schurich, PhD, Kai Neben, MD, Anja Seckinger, MD, Barbara Huegle-Doerr, PhD, Maximilian Merz, MD, Markus Munder, MD, Walter Lindemann, MD, Matthias Zeis, MD, Christian Gerecke, MD, Ingo GH Schmidt-Wolf, MD, Katja Weisel, MD, Christof Scheid, MD, Hans Salwender, MD
Journal: Blood
Blood (2013) 122 (21): 3369.
https://doi.org/10.1182/blood.V122.21.3369.3369
Published: 2013